Novel VEGFR/PDGFR inhibitor well-tolerated in treatment of wet AMD

A new treatment for neovascular age-related macular degeneration was well-tolerated and showed potential efficacy, according to a news release.At the Association for Research in Vision and Ophthalmology meeting, Xcovery Vision released preliminary data from a phase 1/2 clinical trial of the VEGFR/PDGFR inhibitor X-82.

Full Story →